Budget Impact Analysis of Semaglutide for Weight-loss Management in Overweight and Obese U.S. Adults

Document Type

Presentation

Loading...

Media is loading
 

Publication Date

11-17-2021

Comments

Presentation: 28:28

Abstract

Obesity is a serious medical condition that can increase cardiovascular disease, diabetes, and certain cancers. Historically, lifestyle behavior changes and current weight-loss treatments have demonstrated mixed results that fall short of expectations for people trying to manage their weight. In contrast to current weight-loss options, semaglutide, a longer-acting glucagon-like peptide-1 receptor agonist (GLP-1), has shown promising results by demonstrating on average 15% weight loss. The objective of my capstone is to perform a budget impact analysis that estimates the potential budget impact of adding semaglutide to the formulary for a hypothetical U.S. health plan.

Language

English

This document is currently not available here.

Submit Feedback on Presentation

Share

COinS